This trial is active, not recruiting.

Condition breast cancer
Treatment sandostatin
Sponsor Stanford University
Collaborator National Institute on Aging (NIA)
Start date September 2002
End date November 2004
Trial size 115 participants
Trial identifier NCT00226967, 12273, 76389, BRSADJ0006


The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Eligibility Criteria

Female participants at least 35 years old.

Inclusion Criteria: 1. Diagnosis of recurrent or metastatic breast cancer. 2. Karnofsky of 70% or greater. 3. Proficient enough in English to be able to take questionnaires and participate in the required tasks. 4. Living within the Greater Bay Area. 5. Age 35 or older . Exclusion Criteria: 1. Positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis. 2. Active cancers within the past 10 years other than breast cancer, basal cell or squamous cell carcinomas of the skin, or in situ cancer of the cervix. 3. Any other serious medical condition that will effect short term survival 4. History of major psychiatric illness for which patient was hospitalized or medicated, with the exception of depression or anxiety 5. A diagnosis of diabetes.

Additional Information

Official title Stress, Diurnal Cortisol, and Breast Cancer Survival
Principal investigator David Spiegel
Description The purpose of this study is to investigate stress and tonic activation of diurnal cortisol in aging metastatic breast cancer patients; feedback inhibition & activation of cortisol; and stress-induced phasic activation of cortisol.
Trial information was received from ClinicalTrials.gov and was last updated in November 2012.
Information provided to ClinicalTrials.gov by Stanford University.